Page 250 - 2021_10-Haematologica-web

Letters to the Editor
gest that acalabrutinib might be a preferable option for BTK inhibitor–based combination therapy. The safety profile of acalabrutinib in R/R DLBCL patients was con- sistent with previous studies; the most common AE were mainly grades 1 or 2, and did not lead to treatment dis- continuation. The observed activity and favorable safety profile support evaluation of acalabrutinib-based combi- nations in DLBCL. Several clinical trials evaluating the combination of acalabrutinib with chemotherapy in patients with DLBCL are underway, including a phase I/II trial (clinicaltrials.gov Identifier: NCT03571308) that is investigating acalabrutinib in combination with R-CHOP in patients with untreated DLBCL expressing CD20, a phase II trial (clinicaltrials.gov Identifier: NCT04002947) that is studying acalabrutinib in combination with R- CHOP or DA-EPOCH in patients with untreated DLBCL, and a phase III trial that is evaluating the addition of acal- abrutinib to R-CHOP in patients with untreated non- GCB DLBCL (clinicaltrials.gov Identifier: NCT04529772).
Paolo Strati,1 Sven de Vos,2 Jia Ruan,3 Kami J. Maddocks,4 Christopher R. Flowers,1,5 Simon Rule,6 Priti Patel,7 Yan Xu,7 Helen Wei,7 Melanie M. Frigault,7 Roser Calvo8
and Martin J.S. Dyer9
1Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA; 3Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; 4Division of Hematology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; 5Winship Cancer Institute of Emory University, Atlanta, GA, USA; 6Department of Hematology, Plymouth University Medical School, Plymouth, UK; 7AstraZeneca, South San Francisco, CA, USA; 8AstraZeneca, Gaithersburg, MD, USA and 9Ernest and Helen Scott Hematological Research Institute, University of Leicester, Leicester, UK
Correspondence:
MARTIN J.S. DYER - mjsd1@le.ac.uk doi:10.3324/haematol.2021.278654 Received: February 26, 2021.
Accepted: June 18, 2021. Pre-published: July 8, 2021.
Disclosures: PS reported no relevant financial disclosures; SdV reported advisory board participation for Incyte, Bayer, and Genentech; JR reported research funding from Celgene, Pharmacyclics, AstraZeneca, and Seattle Genetics, and consultancy/advisory board participation for Celgene, Pharmacyclics, AstraZeneca, Juno, Kite Pharma, and Cellectar; KJM reported research funding from Pharmacyclics, BMS, Merck, and Novartis, and consultancy for Pharmacyclics, Janssen, Morphosys, Celgene, Karyopharm, and Seattle Genetics; CRF reported consultancy for AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, Pharmacyclics/Janssen, and Spectrum, and research funding from AbbVie, Acerta, Allogene, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Kite, Takeda, Morphosys, Pharmacyclics, TG Therapeutics, Xencor, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation, and Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research); SR reported employment by and stock ownership of VelosBio, research funding from Janssen, and advisory board participation for Janssen Kite; PP, MMF, and RC reported employment by and stock ownership of AstraZeneca; YX reported employment by Acerta Pharma, a member of the AstraZeneca Group at the time of the study; HW reported employment by
AstraZeneca. MJSD reported grants from Astra Zeneca, Gilead, and Roche.
Contributions: all authors contributed to data interpretation, reviewed and provided important intellectual contributions to the manuscript, and approved the final version for publication. Statistical analyses were per- formed by HW.
Funding: the study was funded by Acerta Pharma, South San Francisco, CA, a member of the AstraZeneca Group. Medical writing assistance, funded by Acerta Pharma, was provided by James Street, PhD, and Jennifer Darby, PharmD, of Peloton Advantage, LLC, an OPEN Health company. PS’s salary is supported by the Lymphoma Research Foundation Career Development Award.
References
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
3. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor sig- nalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88- 92.
4. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926.
5. Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411-419.
6. Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2019.
7. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):323-332.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.
9. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
10.Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multi- centre, phase 2 trial. Lancet. 2018;391(10121):659-667.
11. Xu X, Zhu Z, Liu F, et al. BTK inhibitors induce ABC-DLBCL cell apoptosis by inhibiting CYLD phosphorylation [abstract]. Blood. 2019;134(Suppl 1):S5046.
12. Narita Y, Nagane M, Mishima K, et al. Phase 1/2 study of tirabruti- nib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122-133.
13.Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treat- ment aspects. Br J Haematol. 2018;181(3):306-319.
14. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of dif- fuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
15. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogene- sis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.
16. Wright GW, Huang DW, Phelan JD, et al. A probabilistic classifica- tion tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-568.
17.Saad AG, Grada Z, Bishop B, et al. nCounter NanoString assay shows variable concordance with immunohistochemistry-based algorithms in classifying cases of diffuse large B-cell lymphoma according to the cell-of-origin. Appl Immunohistochem Mol Morphol. 2019;27(9):644-648.
18. Fiorcari S, Maffei R, Audrito V, et al. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016;7(40):65968-65981.
19. Strati P, Schlette EJ, Solis Soto LM, et al. Achieving complete remis- sion in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood. 2020;135(7):510-513.
2778
haematologica | 2021; 106(10)